Anemia of Chronic Disorders: New Diagnostic Tools and New Treatment Strategies

Seminars in Hematology

Volumn 52, Issue 4, 2015, Pages 313-320

  Weiss, Guenter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (1 PIPERAZINYL)PHENYL] 3 (4 QUINOLINYL)PYRAZOLO[1,5 A]PYRIMIDINE; ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEMOJUVELIN; HEPARIN DERIVATIVE; HEPCIDIN; HEPCIDIN ANTIBODY; INTERLEUKIN 6; IRON; NOX H 94; OLIGORIBONUCLEOTIDE; PROTEIN ANTIBODY; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ERYTHROPOIETIN;

ANEMIA; ANEMIA OF CHRONIC DISORDER; CHRONIC DISEASE; ERYTHROPOIESIS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPOXIA; IMMUNOREACTIVITY; INCIDENCE; IRON DEFICIENCY ANEMIA; IRON METABOLISM; LABORATORY TEST; MEAN CORPUSCULAR VOLUME; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

ANEMIA; ANIMALS; CHRONIC DISEASE; ERYTHROPOIETIN; HEPCIDINS; HUMANS; IRON;

EID: 84941912205     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.07.004     Document Type: Review

References (71)

1. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
2. Macdougall I.C., Canaud B., de Francisco A.L., et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 2012, 14:882-886.
3. Nissenson A.R., Goodnough L.T., Dubois R.W. Anemia: not just an innocent bystander?. Arch Intern Med 2003, 163:1400-1404.
4. Matzner Y., Levy S., Grossowicz N., Izak G., Hershko C. Prevalence and causes of anemia in elderly hospitalized patients. Gerontology 1979, 25:113-119.
5. Ferrucci L., Semba R.D., Guralnik J.M., et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010, 115:3810-3816.
6. Weinberg E.D. Iron availability and infection. Biochim Biophys Acta 2009, 1790:600-605.
7. Nairz M., Haschka D., Demetz E., Weiss G. Iron at the interface of immunity and infection. Frontiers Pharmacol 2014, 5:152.
8. Weiss G., Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol 2013, 9:205-215.
9. Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011, 62:347-360.
10. Armitage A.E., Eddowes L.A., Gileadi U., et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011, 118:4129-4139.
11. Hentze M.W., Muckenthaler M.U., Galy B., Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010, 142:24-38.
12. Fahmy M., Young S.P. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J 1993, 296:175-181.
13. Ludwiczek S., Aigner E., Theurl I., Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101:4148-4154.
14. Guida C., Altamura S., Klein F.A., et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 2015, 125:2265-2275.
15. Theurl I., Theurl M., Seifert M., et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008, 111:2392-2399.
16. Theurl I., Aigner E., Theurl M., et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009, 113:5277-5286.
17. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011, 589:1251-1258.
18. de Bruin A.M., Demirel O., Hooibrink B., Brandts C.H., Nolte M.A. Interferon-gamma impairs proliferation of hematopoietic stem cells in mice. Blood 2013, 121:3578-3585.
19. Means R.T. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003, 2:116-121.
20. Perlstein T.S., Pande R., Berliner N., Vanasse G.J. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood 2011, 117:2800-2806.
21. Mastrogiannaki M., Matak P., Mathieu J.R., et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 2012, 97:827-834.
22. Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014, 46:678-684.
23. Sonnweber T., Nachbaur D., Schroll A., et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 2014, 63:1951-1959.
24. Thomas C., Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005, 11:14-23.
25. Punnonen K., Suominen P., Kuusinen A., Kuiper-Kramer E. Clinical use of soluble transferrin receptor. Clin Chem Lab Med 2000, 38:377.
26. Goodnough L.T., Nemeth E., Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010, 116:4754-4761.
27. Thomas L., Franck S., Messinger M., Linssen J., Thome M., Thomas C. Reticulocyte hemoglobin measurement-comparison of two methods in the diagnosis of iron-restricted erythropoiesis. Clin Chem Lab Med 2005, 43:1193-1202.
28. Van Wyck D.B., Roppolo M., Martinez C.O., Mazey R.M., McMurray S. United States Iron Sucrose Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005, 68:2846-2856.
29. Urrechaga E., Borque L., Escanero J.F. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hematol 2013, 35:144-149.
30. van Santen S., van Dongen-Lases E.C., de Vegt F., et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum 2011, 63:3672-3680.
31. Ganz T., Olbina G., Girelli D., Nemeth E., Westerman M. Immunoassay for human serum hepcidin. Blood 2008, 112:4292-4297.
32. Kroot J.J., Tjalsma H., Fleming R.E., Swinkels D.W. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011, 57:1650-1669.
33. Weiss G., Theurl I., Eder S., et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009, 39:883-890.
34. Kroot J.J., van Herwaarden A.E., Tjalsma H., Jansen R.T., Hendriks J.C., Swinkels D.W. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol 2012, 87:977-983.
35. Girelli D., Trombini P., Busti F., et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011, 96:500-506.
36. Gutschow P., Schmidt P.J., Han H., et al. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis. Haematologica 2015, 100:167-177.
37. Lasocki S., Baron G., Driss F., et al. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med 2010, 36:1044-1048.
38. Prentice A.M., Doherty C.P., Abrams S.A., et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012, 119:1922-1928.
39. Theurl M., Nairz M., Schroll A., et al. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica 2014, 99:1516-1524.
40. Oexle H., Gnaiger E., Weiss G. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta 1999, 1413:99-107.
41. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011, 17:899-906.
42. Hershko C., Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood 2014, 123:326-333.
43. Nemeth E., Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014, 28:671-681. vi.
44. Drueke T.B., Parfrey P.S. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012, 82:952-960.
45. Bennett C.L., Spiegel D.M., Macdougall I.C., et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012, 38:783-796.
46. Spahn D.R., Goodnough L.T. Alternatives to blood transfusion. Lancet 2013, 381:1855-1865.
47. Sun C.C., Vaja V., Babitt J.L., Lin H.Y. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012, 87:392-400.
48. Sasu B.J., Cooke K.S., Arvedson T.L., et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010, 115:3616-3624.
49. Cooke K.S., Hinkle B., Salimi-Moosavi H., et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013, 122:3054-3061.
50. Grebenchtchikov N., Geurts-Moespot A.J., Trentmann S., et al. Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidin. Clin Chem 2014, 60:897-899.
51. van Eijk L.T., John A.S., Schwoebel F., et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 2014, 124:2643-2646.
52. Babitt J.L., Huang F.W., Wrighting D.M., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38:531-539.
53. Boser P., Seemann D., Liguori M.J., et al. Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation. APS J 2015, 17:930-938.
54. Babitt J.L., Huang F.W., Xia Y., Sidis Y., Andrews N.C., Lin H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007, 117:1933-1939.
55. Silvestri L., Pagani A., Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008, 111:924-931.
56. Theurl I., Schroll A., Sonnweber T., et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011, 118:4977-4984.
57. Meynard D., Kautz L., Darnaud V., Canonne-Hergaux F., Coppin H., Roth M.P. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009, 41:478-481.
58. Andriopoulos B., Corradini E., Xia Y., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009, 41:482-487.
59. Yu P.B., Hong C.C., Sachidanandan C., et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008, 4:33-41.
60. Sun C.C., Vaja V., Chen S., et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013, 28:1733-1743.
61. Poli M., Asperti M., Naggi A., et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 2014, 123:1564-1573.
62. Poli M., Asperti M., Ruzzenenti P., Regoni M., Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Frontiers Pharmacol 2014, 5:86.
63. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015, 372:1832-1843.
64. Kautz L., Jung G., Nemeth E., Ganz T. Erythroferrone contributes to recovery from anemia of inflammation. Blood 2014, 124:2569-2574.
65. Mastrogiannaki M., Matak P., Keith B., Simon M.C., Vaulont S., Peyssonnaux C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009, 119:1159-1166.
66. Soni H. Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia. Med Hypoth 2014, 82:547-550.
67. Wilkinson N., Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2alpha mRNA translation. Blood 2013, 122:1658-1668.
68. Vecchi C., Montosi G., Zhang K., et al. ER stress controls iron metabolism through induction of hepcidin. Science 2009, 325:877-880.
69. Nairz M., Schroll A., Moschen A.R., et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kappaB-inducible immune pathways. Immunity 2011, 34:61-74.
70. Song S.N., Tomosugi N., Kawabata H., Ishikawa T., Nishikawa T., Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010, 116:3627-3634.
71. Nairz M., Schroll A., Demetz E., Tancevski I., Theurl I., Weiss G. 'Ride on the ferrous wheel'-the cycle of iron in macrophages in health and disease. Immunobiology 2015, 220:280-294.